Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED (CSL)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
138.1(c) 138.95(c) 141.45(c) 140.95(c) 139.92 Last
500 716 564 897 934 722 885 928 779 190 Volume
+0.32% +0.62% +1.80% -0.35% -0.73% Change
More quotes
Financials ($)
Sales 2018 7 444 M
EBIT 2018 2 097 M
Net income 2018 1 598 M
Debt 2018 3 463 M
Yield 2018 1,43%
Sales 2019 8 097 M
EBIT 2019 2 394 M
Net income 2019 1 836 M
Debt 2019 3 210 M
Yield 2019 1,58%
P/E ratio 2018 31,47
P/E ratio 2019 27,44
EV / Sales2018 7,17x
EV / Sales2019 6,56x
Capitalization 49 894 M
More Financials
Company
CSL Ltd. is a biopharmaceutical company.It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions.The company operates its business through two segments: CSL Behring and bioCSL.The CSL Behring segment provides... 
Sector
Pharmaceuticals
Calendar
12/04 | 11:00pmR&D Day
More about the company
Surperformance© ratings of CSL Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on CSL LIMITED
10/16 CSL : Australian Scientists awarded $2.5m to support ground-breaking medical res..
10/16 CSL : Behring Trains Employees to Save Lives in Their Communities and Workplace ..
10/13 CSL : Federal Contracts Awarded by Federal Agencies in Minnesota (Oct. 13)
10/12 CSL : $986,855 Federal Contract Awarded to CSL Behring
10/03 CSL : Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA CSL Behrin..
10/02 CSL : Behring - Patient Groups Sharpen Their Capabilities to Protect Access to M..
09/21 CSL : Behring Announces FDA Approval of Privigen® for the Treatment of Chronic I..
09/19 CSL : Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT for People Five Year..
09/14 SEQIRUS : Receives FDA Approval of AFLURIA QUADRIVALENT® (Influenza Vaccine) for..
09/13 SEQIRUS : Donates Influenza Vaccine for Hurricane Harvey Relief in Texas
More news
Sector news : Biopharmaceuticals
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Biopharmaceuticals
Latest Tweets
10/20#TheWalkingDead boss Greg Nicotero says zombies will win the Rick-Negan war
21
10/18CSL avoids second strike after executive pay overhaul.  
10/18CSL to change CEO pay structure after revolt  
10/18TRADING DAY: via @SamWoodhill $CSL bows to shareholders' executive pay press..
1
10/18CSL avoids a second strike on remuneration report at AGM, reports @OBenPotter.. 
More tweets
Qtime:229
News from SeekingAlpha
10/18 CSL (CSLLY) Investor Presentation - Slideshow
08/22 CSL Limited Leader In High Growth Plasma Sales To China
08/10 CSL reports Q2 results
06/13 CSL (CMXHF) Acquires Wuhan Zhong Yuan Rui De Biological Products - Slideshow
2016 EWA : Getting In Down Under
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | 4-Traders
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 108 $
Spread / Average Target -1,6%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
John Shine Chairman
David Mark Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer
David Westbrook Anstice Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED38.38%49 894
BIOGEN31.85%71 485
ALEXION PHARMACEUTICALS14.80%31 027
GRIFOLS SA30.11%17 818
BIOMARIN PHARMACEUTICAL6.98%15 380
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 941